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ABSTRACT
Opioids are extremely effective in managing cancer pain, and now are utilized for longer periods of time in 
cancer patients as the treatment for malignancies has become more successful.[1] The goals in cancer pain 
treatment includes maintaining function in patients with cancer pain (especially in earlier stage disease), and 
palliation in advanced disease.[1] The perception of the lay public and inexperienced clinicians that addiction 
is inevitable, often leads to an inappropriate fear to utilize opioids to appropriately manage pain; resulting in 
persistent under-treatment of cancer pain internationally.[2,3] There is much confusion about the phenomenon 
of physical dependence and how this can be differentiated from the maladaptive behaviors that constitute a 
diagnosis of substance abuse. The burden of cancer and associated cancer pain is projected to continue to rise, 
and is often at an advanced stage at diagnosis in less developed countries.[4] To be able to provide quality care 
for this patient population availability of opioids and skilled clinicians in pain management is paramount. In the 
majority of cases, the main concern is to abate concerns about risks of opioid addiction; to allow adequate pain 
relief. To understand the infrequent phenomenon of substance abuse in the setting of cancer pain management 
clear definitions are needed, and review of the epidemiology of occurrence in cancer populations is needed. It is 
also important to clearly separate the issues of substance abuse at the patient level and diversion of prescribed 
opioids. There are principles of managing cancer pain in the rare clinical scenario when the risk of substance 
abuse is high, which can still allow safe management of cancer pain with opioids. 
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DEFINITIONS
There is a significant variability in terminology utilized 
in research and clinical practice; and terms can lead 
to clinicians confusing pharmacological phenomena 
with abuse and addiction.[2] Maladaptive behaviors as 
defined by DSM IV–R need to be identified as being 
outside cultural and societal norms, also in the context 
of  deterioration physical and psychosocial functioning 
related to progressive disease these changes can mimic 
core domains to identify “addiction”.[2] Equally a cancer 
patient who requests a specific opioid by a specific route 
may be demonstrating a good knowledge of  their own 
cancer pain management and be assertive in the way 
they navigate health care systems.[2] The following are 
helpful definitions to use
Tolerance
Tolerance is a “pharmacological property defined by the 
need for increasing doses to maintain the effect of  the 
agent”.[2] In cancer pain management tolerance to some 
adverse effects may occur, but tolerance to analgesic 
effects requiring the need to escalate dose escalation is 
rare, and the need for dose escalation is usually in the 
context of  a progressive painful lesion or new lesion 
developing.[2]
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Physical dependence
Physical dependence is defined as the occurrence of  a 
withdrawal after abrupt dose reduction or an administration 
of  an agonist.[2]
Substance dependence and abuse
The DSM IV criteria for substance abuse and substance 
dependence provide definitions for maladaptive patterns 
of  substance abuse, where the defining factor is compulsive 
drug seeking behavior.[1,2,5] 
Pseudo-addiction
The phenomena of  “opioid seeking” may be seen when 
someone is experience unrelenting unrelieved pain and this 
is not be confused with substance dependence.[1,6]
CLINICAL ISSUES RELATED TO PHYSICAL 
DEPENDENCE
The administration of  an opioid antagonist or a 
mixed agonist–antagonist to person who has physical 
dependence will precipitate a withdrawal syndrome.[6] 
Opioid withdrawal is characterized by features including 
anxiety, nervousness, irritability, chills and hot flushes, 
salivation, lacrimation, rhinorrhoea, sneezing, sweating, 
gooseflesh, nausea and vomiting, abdominal cramps, and 
insomnia.[6] The time course of  withdrawal is determined 
by the elimination half  life of  the opioid.[6] The avoidance 
of  withdrawal has been proposed to support drug 
seeking behaviors, however, in cancer patients who 
pain is reduced or disappears due to effective anticancer 
therapies (e.g., radiation for painful bone metastasis) 
routine reduction or cessation of  opioids occurs without 
significant issues.[2] It is proposed that reducing opioid 
doses to 75% of  the previous daily dose and a down 
titration approach until dose is discontinued prevents 
withdrawal symptoms.[6]
PREVALENCE OF SUBSTANCE ABUSE IN CANCER 
PATIENTS
There have been several studies exploring the prevalence 
of  opioid addiction in medical illness. The most notable 
was the Boston Collaborative surveillance project, which 
only identified 4 cases of  addiction out of  11,882 inpatients 
prescribed opioids.[7] The rates of  substance abuse remain 
low and stable despite increased medical use of  opioid 
analgesics, and this has also been replicated in study of  
1723 outpatients and community care patients in an Indian 
context.[1,2,4] 
Opioids used to manage cancer pain for patients with no 
prior history of  substance abuse or addiction, is rarely 
associated with new onset of  substance disorder.[2,7-9] 
The current understanding of  the patho-physiology and 
etiology of  substance abuse, supports the conclusion 
that the risk of  de novo substance abuse or addiction when 
opioids are used for appropriate medical indications, is 
extremely low if  no personal or family history or abuse 
or addiction or significant premorbid psychiatric disorder 
exists.
PRINCIPLES OF CANCER PAIN MANAGEMENT 
WHEN PRIOR SUBSTANCE ABUSE OR RISK 
EXISTS
Policy level
Policies need to be in place to allow secure storage of  
opioid medication stock, maintenance of  records and 
stock registers and judicious prescribing by appropriately 
trained clinicians.[4] There are well-developed protocols 
internationally which meet these criteria stringently. 
Proper disposal of  unused drugs and used opioid patches 
is also important. It is important that regulatory bodies 
and clinicians meet to discuss these issues so that the 
correct balance between drug control, and ensuring opioid 
availability for medical use occurs.[10]
Clinician level
Clinicians need to be adequately trained in pain management, 
and the prescription and monitoring of  opioid therapy; and 
have a responsibility to provide education to the patient 
and their family about their safe use, and adverse effect 
monitoring. A comprehensive history and assessment is 
needed prior to the commencement of  opioid therapy, 
and attention to specific risks such as family history or 
significant premorbid psychiatric conditions.[1] Equally for 
the majority of  patients, clinicians need to be comfortable 
allaying unfounded fears of  opioid addiction, so that 
patients can receive adequate pain relief.
Patient level
People with a history of  abuse of  opioids may develop 
cancer and associated pain syndromes; which in some 
cases may require opioid therapy for adequate relief.[11] 
In the at risk patient or a patient with known substance 
abuse, structure and a multidisciplinary approach is very 
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useful, and it is important to realize/acknowledge they 
have significant cancer pain.[2] It is useful to have open and 
empathic communication with the patient about their drug 
use rather than avoid the topic. Assessment and treatment 
of  comorbid psychiatric disorders is crucial for success of  
management in many patients. Opioids with slower onset or 
longer duration may be more appropriate choices; and the 
oral route is preferred.[1,6] The aim of  therapy is usually harm 
reduction-minimizing harm from unrelieved pain balanced 
with harm due to substance abuse both to the patient and 
their surroundings.[6] Clear expectations in a written contract 
can be helpful for some patients and frequent monitoring 
with prescribing and dispensing by a single provider of  a 
supply for a limited number of  days (contingent on the 
patient coming for regular review). In the inpatient setting 
the clinical team need to be aware withdrawal symptoms 
may occur, and this may be related to more than one drug 
(and this includes alcohol and nicotine).
In the setting that an aberrant drug related behavior is 
identified, a comprehensive assessment and interpretation 
of  these behaviors needs to be undertaken to determine the 
underlying cause, from a range of  differential diagnoses. [2] 
The request for higher doses may be due to intractable 
pain, other underlying psychiatric diagnosis, which 
increase likelihood of  the fear associated with a cancer 
diagnosis being manifested as impulsivity or aberrant 
drug taking, or self  medication for coexisting symptoms 
such as depression, anxiety or insomnia. The patient may 
have a cognitive impairment or be confused about their 
medication regimen.
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